Faruqi & Faruqi Reminds Rentokil Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 27, 2025 - RTO

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rentokil Initial plc due to alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Allegations Against Rentokil - The complaint alleges that Rentokil and its executives made false and misleading statements regarding the integration of Terminix, leading to significant execution challenges [4]. - Specific issues cited include disruption during the early integration pilots, ongoing execution challenges, and the failure to integrate Terminix, which negatively impacted organic revenue growth in North America [4]. - The allegations suggest that Rentokil's positive statements about its business and prospects were materially false and lacked a reasonable basis [4]. Group 2: Financial Impact and Market Reaction - On April 18, 2024, Rentokil reported only 1.5% organic revenue growth in North America for Q1 2024, below the guidance of 2%, leading to a 9% drop in the stock price [5]. - A subsequent trading update on September 11, 2024, revealed an expected 1% organic revenue growth for the second half of 2024, causing a further 21% decline in stock price [6]. - The CEO and CFO acknowledged execution challenges during the conference call, indicating that the integration efforts had not been successful [6]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $75,000 in Rentokil between December 1, 2023, and September 10, 2024, are encouraged to discuss their legal rights with Faruqi & Faruqi [1]. - The deadline to seek the role of lead plaintiff in the federal securities class action against Rentokil is January 27, 2025 [2]. - Any member of the putative class can move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [7].